RENATA Stock Overview
Manufactures, markets, and distributes human pharmaceuticals, animal health medicines, nutritionals, and vaccines in Bangladesh. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 3/6 |
| Dividends | 3/6 |
My Notes
Capture your thoughts, links and company narrative
Renata PLC Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ৳501.30 |
| 52 Week High | ৳1,070.50 |
| 52 Week Low | ৳495.00 |
| Beta | 0.063 |
| 1 Month Change | -20.42% |
| 3 Month Change | -25.49% |
| 1 Year Change | -53.17% |
| 3 Year Change | -60.57% |
| 5 Year Change | -40.49% |
| Change since IPO | 17,101.75% |
Recent News & Updates
Recent updates
Shareholder Returns
| RENATA | BD Pharmaceuticals | BD Market | |
|---|---|---|---|
| 7D | 0.4% | -0.05% | 1.0% |
| 1Y | -53.2% | -30.2% | -19.4% |
Return vs Industry: RENATA underperformed the BD Pharmaceuticals industry which returned -30.4% over the past year.
Return vs Market: RENATA underperformed the BD Market which returned -19.3% over the past year.
Price Volatility
| RENATA volatility | |
|---|---|
| RENATA Average Weekly Movement | 3.0% |
| Pharmaceuticals Industry Average Movement | 5.2% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in BD Market | 6.9% |
| 10% least volatile stocks in BD Market | 2.5% |
Stable Share Price: RENATA has not had significant price volatility in the past 3 months compared to the BD market.
Volatility Over Time: RENATA's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1972 | 7,859 | Syed S. Kabir | www.renata-ltd.com |
Renata PLC manufactures, markets, and distributes human pharmaceuticals, animal health medicines, nutritionals, and vaccines in Bangladesh. Its pharmaceutical products include antimicrobials, anti-hypertensive, anti-angina, anti-diabetic, eye-ear and topical preparation, antigout, NSAID, anti-spasmodic, steroid, anti-osteoporotic, anti-allergic, cardiovascular, CNS, hormone, anti-cancer, oxytocic, anti-fibrinolytic, anti-asthma, expectorant, oral rehydration saline, narcotic analgesic, antipyretic/analgesic, antiemetic, anesthetic, antiviral, and other products. The company offers lipid lowering, antiulcer, anti-parasitic and anti-protozoal, anti-fungal, anti-tuberculosis, and gastroprokinetic agents; and vitamins and minerals.
Renata PLC Fundamentals Summary
| RENATA fundamental statistics | |
|---|---|
| Market cap | ৳57.50b |
| Earnings (TTM) | ৳2.96b |
| Revenue (TTM) | ৳39.91b |
19.4x
P/E Ratio1.4x
P/S RatioIs RENATA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RENATA income statement (TTM) | |
|---|---|
| Revenue | ৳39.91b |
| Cost of Revenue | ৳23.13b |
| Gross Profit | ৳16.78b |
| Other Expenses | ৳13.82b |
| Earnings | ৳2.96b |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 25.78 |
| Gross Margin | 42.04% |
| Net Profit Margin | 7.41% |
| Debt/Equity Ratio | 55.7% |
How did RENATA perform over the long term?
See historical performance and comparisonDividends
1.8%
Current Dividend Yield36%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/06 05:28 |
| End of Day Share Price | 2025/02/06 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Renata PLC is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Asif Khan | EDGE Research & Consulting |
| Fahad Shaikh | EFG-Hermes Research |
| M'Sekiwa Simbarashe Mutukwa | Renaissance Capital |